2020-05-07
Camurus Interim Report January-March 2020
”The number of patients treated with Buvidal® increased by 90 percent in the quarter”
Read the full report on Camurus website: https://www.camurus.com/investors/
2020-05-07
”The number of patients treated with Buvidal® increased by 90 percent in the quarter”
Read the full report on Camurus website: https://www.camurus.com/investors/
2019-04-10
Aimpoint has been awarded a large contract of USD 24 million from the U.S. Military for the FCS13-RE system for SAAB…
Read more2019-04-10
Camurus’ rights issue of 403 MSEK has been oversubscribed. The rights issue was carried out to secure financing of t…
Read more2019-04-10
New positive results from a Phase 3 study show that Camurus’ Buvidal® provides better treatment effect for fentanyl…
Read more2019-04-10
Camurus’ partner, Braeburn Inc., has initiated court proceedings foran approval of Brixadi (Buvidal® in the US) and…
Read more2019-02-26
Based on Aimpoint's red dot sight for fire arms, the company has developed a commercial VR platform, GAIM, which is…
Read more